Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Vie + some more technical info. Ombitasvir is a potent, orally administered small molecule inhibitor of the HCV nonstructural protein 5A NS5A replication complex that reduces viral RNA replication and interferes with virion assembly; it is used as part of combination regimens to provide complementary mechanisms that limit resistance emergence. The substance is characterized by low aqueous solubility and high plasma protein binding, and quality control focuses on assay by validated HPLC and mass spectrometry methods, stability under controlled conditions, and confirmation of related substances and residual solvents to meet regulatory requirements for combination antiviral products.
Parent: Ombitasvir
Process-related and degradation impurities commonly monitored for ombitasvir include dealkylated derivatives, desmethyl species, N-oxide forms, hydrolysis products of labile moieties, and oxidative by-products; these are routinely identified and quantified by LC-MS and HPLC with diode array detection. Typical analytical acceptance criteria used in API control and batch release are individual identified or qualified related compounds at or below 0.5 percent w/w, individual unspecified impurities at or below 0.10 percent w/w, and total impurities not exceeding 1.0 percent w/w, with limits for residual solvents and elemental impurities set by ICH Q3C and Q3D guidance; final specification values are established in the regulatory dossier and may differ by manufacturer and finished product.
Ombitasvir binds to the HCV nonstructural protein 5A NS5A replication complex, disrupting its role in viral RNA replication and virion assembly, which leads to a rapid decline in intracellular viral RNA when used in combination regimens.
Ombitasvir is a direct acting antiviral and belongs to the NS5A inhibitor class of HCV therapies.
